Clinical Scorecard: Evaluating the Cardiorenal Benefits of Dapagliflozin and Valsartan in Individuals with Type 2 Diabetes and Hypertension: A Retrospective Cohort Analysis

At a Glance

Key Highlights

• Combination of dapagliflozin (10 mg/day) with valsartan (80 mg/day) showed superior reductions in blood pressure and glycemic parameters compared to valsartan monotherapy.
• Significant improvements in inflammatory and cardiac biomarkers, echocardiographic measures, renal function, and fibrosis markers were observed with combination therapy.
• Multivariate analysis confirmed combination therapy as an independent predictor of better cardiorenal outcomes (OR = 2.417, 95% CI: 1.315–4.443, P = 0.004).

Guideline-Based Recommendations

Diagnosis

• Confirm T2DM diagnosis per established diabetes guidelines.
• Confirm hypertension diagnosis per hypertension management guidelines.
• Assess baseline cardiac and renal function including echocardiography and biomarkers.

Management

• Use valsartan 80 mg/day as standard RAAS blockade therapy for hypertension in T2DM patients.
• Add dapagliflozin 10 mg/day to valsartan to achieve superior cardiorenal protection.
• Target multifactorial control including blood pressure, glycemic variability, inflammation, and fibrosis.

Monitoring & Follow-up

• Monitor blood pressure and glycemic parameters (FPG, 2hPG, glycemic variability indices) regularly.
• Assess inflammatory and cardiac biomarkers (hs-CRP, TNF-α, IL-6, IL-33, sST2, sICAM-1) periodically.
• Evaluate renal function (eGFR, UACR, SCr, BUN) and fibrosis markers (PIIINP, C-IV, LN, TGF-β1) during follow-up.
• Perform echocardiographic assessments (LVEF, LVEDD, LVESD, LAD, IVSd) to monitor cardiac function.

Risks

• Potential adverse effects related to SGLT2 inhibitors and ARBs should be monitored according to standard clinical practice.
• No specific safety concerns detailed in this study; clinical vigilance recommended.

Patient & Prescribing Data

Patients with coexisting type 2 diabetes mellitus and hypertension, aged 18 years or older, on stable therapy for at least 24 weeks.

Combination therapy with dapagliflozin and valsartan is associated with enhanced cardiorenal benefits compared to valsartan monotherapy, including improved blood pressure control, glycemic management, reduced inflammation, better cardiac function, and renal protection.

Clinical Best Practices

• Employ propensity score matching or similar methods to minimize confounding in observational studies assessing combination therapies.
• Adopt combination therapy targeting multiple pathophysiological pathways in high-risk T2DM and hypertensive patients for optimal cardiorenal outcomes.
• Regularly monitor comprehensive biomarker panels and echocardiographic parameters to evaluate therapy effectiveness beyond conventional clinical measures.

References

• Guidelines for the prevention and treatment of type 2 diabetes
• Guidelines for the management of hypertension